ReviewExpert opinion on drug metabolism & toxicology2008
Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering.
Review in Expert opinion on drug metabolism & toxicology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- The non-linear and linear effects of CYP2C19 metaboliser status on DNA methylation: a methylome-wide association study.Clinical epigenetics · 2026Article
- Sensitive Profiling of Mouse Liver Membrane Proteome Dysregulation Following a High-Fat and Alcohol Diet Treatment.Proteomics · 2024Article
- Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.Biomedicines · 2024Review
- The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy-Literature Review.Journal of clinical medicine · 2022Review
- Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies.Diabetologia · 2022Review
- Article
- Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis.BMC complementary medicine and therapies · 2021Article
- Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.JCI insight · 2020Article
- Maternal diet intervention before pregnancy primes offspring lipid metabolism in liver.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- Effects of Dietary Apple Polyphenols Supplementation on Hepatic Fat Deposition and Antioxidant Capacity in Finishing Pigs.Animals : an open access journal from MDPI · 2019Article
- Advances in Cardiovascular Disease Lipid Research Can Provide Novel Insights Into Mycobacterial Pathogenesis.Frontiers in cellular and infection microbiology · 2019Review
- Biochemical properties of cholesterol aldehyde secosterol and its derivatives.Journal of clinical biochemistry and nutrition · 2018Review
- The role of dyslipidemia in diabetic retinopathy.Vision research · 2017Review
- Common structural features of cholesterol binding sites in crystallized soluble proteins.Journal of lipid research · 2017Review
- Identification and analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in cynomolgus macaques.The Journal of veterinary medical science · 2014Article
- Cytochromes p450: roles in diseases.The Journal of biological chemistry · 2013Review
- In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.Molecular pharmacology · 2012Article
- Effects of feeding potato pulp on cholesterol metabolism and its association with cecal conditions in rats.Plant foods for human nutrition (Dordrecht, Netherlands) · 2011Article
- Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function.Biochemistry · 2011Article
- Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain.Journal of proteome research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) continues to be a leading cause of death worldwide. Elevated serum cholesterol is one of the classical risk factors for CVD, which also include age, hypertension, smoking, diabetes mellitus, obesity and family history. Several therapeutic drug classes have been developed to treat hypercholesterolemia; yet, an important percentage of patients do not reach their treatment goals. Therefore, new cholesterol-lowering medications that have sites of action different from that of drugs available at present need to be developed. This review summarizes new information about cytochrome P450 enzymes 7A1, 27A1 and 46A1. These enzymes play key roles in cholesterol elimination and have the potential to serve as targets for cholesterol-lowering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.